Does the media favor VKTX or MDGL?

In the previous week, Viking Therapeutics had 12 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 15 mentions for Viking Therapeutics and 3 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.01 beat Viking Therapeutics' score of 0.97 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Madrigal Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LLY or VKTX?

In the previous week, Eli Lilly and Company had 101 more articles in the media than Viking Therapeutics. MarketBeat recorded 116 mentions for Eli Lilly and Company and 15 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.19 beat Viking Therapeutics' score of 0.97 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 84 Very Positive mention(s) 14 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Viking Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer PFE or VKTX?

In the previous week, Pfizer had 29 more articles in the media than Viking Therapeutics. MarketBeat recorded 44 mentions for Pfizer and 15 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.97 beat Pfizer's score of 0.75 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 23 Very Positive mention(s) 9 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive Viking Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor VKTX or BBIO?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 24 mentions for BridgeBio Pharma and 15 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.97 beat BridgeBio Pharma's score of 0.27 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive BridgeBio Pharma 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to EXEL or VKTX?

In the previous week, Exelixis had 6 more articles in the media than Viking Therapeutics. MarketBeat recorded 21 mentions for Exelixis and 15 mentions for Viking Therapeutics. Exelixis' average media sentiment score of 1.00 beat Viking Therapeutics' score of 0.97 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Viking Therapeutics (VKTX) Competitors

$32.70 -0.98 (-2.91%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$33.00 +0.30 (+0.92%)

As of 09/9/2026 07:57 PM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, BBIO, and EXEL

Should you buy Viking Therapeutics stock or one of its competitors? Viking Therapeutics's main competitors and comparable companies include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), BridgeBio Pharma (BBIO), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Viking Therapeutics had 12 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 15 mentions for Viking Therapeutics and 3 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.01 beat Viking Therapeutics' score of 0.97 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics currently has a consensus price target of $96.63, indicating a potential upside of 195.49%. Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 27.99%. Given Viking Therapeutics' higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, meaning that its share price is 198% less volatile than the broader market.

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Madrigal Pharmaceuticals	$958.40M	13.18	-$288.28M	-$12.89	N/A

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Madrigal Pharmaceuticals beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eli Lilly and Company currently has a consensus target price of $1,292.18, suggesting a potential upside of 15.02%. Viking Therapeutics has a consensus target price of $96.63, suggesting a potential upside of 195.49%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	16.23	$20.64B	$29.80	37.70
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Eli Lilly and Company has a net margin of 33.53% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 97.83% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	33.53%	97.83%	23.23%
Viking Therapeutics	N/A	-94.56%	-82.75%

Eli Lilly and Company has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

In the previous week, Eli Lilly and Company had 101 more articles in the media than Viking Therapeutics. MarketBeat recorded 116 mentions for Eli Lilly and Company and 15 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.19 beat Viking Therapeutics' score of 0.97 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	84 Very Positive mention(s)	14 Positive mention(s)	13 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Viking Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Pfizer (NYSE:PFE) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pfizer has a net margin of 6.80% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.63% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Viking Therapeutics	N/A	-94.56%	-82.75%

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.53	$7.77B	$0.76	36.61
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Pfizer currently has a consensus price target of $28.28, suggesting a potential upside of 1.63%. Viking Therapeutics has a consensus price target of $96.63, suggesting a potential upside of 195.49%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

In the previous week, Pfizer had 29 more articles in the media than Viking Therapeutics. MarketBeat recorded 44 mentions for Pfizer and 15 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.97 beat Pfizer's score of 0.75 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	23 Very Positive mention(s)	9 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
Viking Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Pfizer beats Viking Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to BridgeBio Pharma?

Viking Therapeutics (NASDAQ:VKTX) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, BridgeBio Pharma had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 24 mentions for BridgeBio Pharma and 15 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.97 beat BridgeBio Pharma's score of 0.27 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
BridgeBio Pharma	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viking Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
BridgeBio Pharma	$502.08M	29.62	-$724.93M	-$3.57	N/A

Viking Therapeutics currently has a consensus target price of $96.63, suggesting a potential upside of 195.49%. BridgeBio Pharma has a consensus target price of $101.53, suggesting a potential upside of 33.45%. Given Viking Therapeutics' higher possible upside, research analysts clearly believe Viking Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Viking Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Summary

BridgeBio Pharma beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Exelixis has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.34
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Exelixis has a net margin of 35.33% compared to Viking Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Viking Therapeutics	N/A	-94.56%	-82.75%

In the previous week, Exelixis had 6 more articles in the media than Viking Therapeutics. MarketBeat recorded 21 mentions for Exelixis and 15 mentions for Viking Therapeutics. Exelixis' average media sentiment score of 1.00 beat Viking Therapeutics' score of 0.97 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Exelixis presently has a consensus target price of $50.07, suggesting a potential downside of 14.17%. Viking Therapeutics has a consensus target price of $96.63, suggesting a potential upside of 195.49%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

85.3% of Exelixis shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Exelixis beats Viking Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.93B	$3.90B	$7.22B	$12.88B
Dividend Yield	N/A	3.61%	2.55%	9.95%
P/E Ratio	-7.02	12.94	271.79	25.29
Price / Sales	N/A	1,459.53	709.72	113.02
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	5.79	15.81	10.63	6.26
Net Income	-$359.64M	-$22.81M	$3.48B	$357.86M
7 Day Performance	-3.77%	-0.13%	-1.19%	-0.56%
1 Month Performance	-5.05%	4.54%	1.99%	-1.04%
1 Year Performance	26.40%	46.20%	21.89%	11.31%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	3.0692 of 5 stars	$32.70 -2.9%	$96.63 +195.5%	+29.4%	$3.93B	N/A	N/A	20	Options Volume
MDGL Madrigal Pharmaceuticals	3.2171 of 5 stars	$546.93 +1.5%	$699.64 +27.9%	+21.8%	$12.45B	$958.40M	N/A	90	Positive News
LLY Eli Lilly and Company	4.9587 of 5 stars	$1,160.52 +0.0%	$1,292.18 +11.3%	+49.8%	$1.09T	$65.18B	38.94	50,000	Trending News Analyst Forecast
PFE Pfizer	3.6029 of 5 stars	$29.02 +1.7%	$28.28 -2.6%	+12.5%	$162.73B	$63.70B	38.19	75,000	Trending News
BBIO BridgeBio Pharma	3.0442 of 5 stars	$76.50 -0.1%	$101.53 +32.7%	+42.2%	$14.97B	$502.08M	N/A	400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BBIO, and EXEL

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Summary

How does Viking Therapeutics compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, BBIO, and EXEL

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Does the media favor VKTX or MDGL?

Do analysts rate VKTX or MDGL?

Which has more risk and volatility, VKTX or MDGL?

Is VKTX or MDGL more profitable?

Which has better valuation and earnings, VKTX or MDGL?

Do institutionals and insiders believe in VKTX or MDGL?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Do institutionals and insiders hold more shares of LLY or VKTX?

Do analysts prefer LLY or VKTX?

Which has better earnings and valuation, LLY or VKTX?

Is LLY or VKTX more profitable?

Which has more volatility and risk, LLY or VKTX?

Does the media refer more to LLY or VKTX?

Summary

How does Viking Therapeutics compare to Pfizer?

Do institutionals and insiders hold more shares of PFE or VKTX?

Is PFE or VKTX more profitable?

Which has stronger valuation & earnings, PFE or VKTX?

Do analysts rate PFE or VKTX?

Which has more volatility and risk, PFE or VKTX?

Does the media prefer PFE or VKTX?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Does the media favor VKTX or BBIO?

Which has more volatility & risk, VKTX or BBIO?

Do institutionals and insiders have more ownership in VKTX or BBIO?

Which has stronger earnings & valuation, VKTX or BBIO?

Do analysts prefer VKTX or BBIO?

Is VKTX or BBIO more profitable?

Summary

How does Viking Therapeutics compare to Exelixis?

Which has preferable valuation & earnings, EXEL or VKTX?

Is EXEL or VKTX more profitable?

Does the media refer more to EXEL or VKTX?

Which has more volatility & risk, EXEL or VKTX?

Do analysts recommend EXEL or VKTX?

Do insiders & institutionals have more ownership in EXEL or VKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools